Académique Documents
Professionnel Documents
Culture Documents
Unstable Angina:
• May present with nonspecific or transient STsegment depressions
or elevations
Diagnosis
Evolving RiskStratification
• Provides prognostic information
• Determines treatment and level of
intervention
Low risk patients ---> early discharge,
High risk ---> admission to highcare
• Helps decongest the casualty and make
available medical resources to more
needy patients.
• Risk stratification should be ongoing – at
admission, 6-8 hrs, 24hrs, discharge
Evolving risk stratification…
Intermediate-risk NSTEACS
YES NO
• admit to CCU or high dependency unit: • undertake stress test (e.g. exercise ECG):
estimate ischemic risk, estimate →positive – refer for angiography to determine
bleeding risk, choose augmented surgery/PCI, or medical therapy
antithrombotic therapy →negative – proceed to discharge patient with
→refer for angiography to determine urgent cardiac follow-up (on upgraded medical
surgery/PCI, or medical therapy. therapy) according to long-term management
after control of myocardial ischemia.
Evolving risk stratification…
Appropriate period of
observation. Consider if
stress test (e.g. exercise
ECG) needed?
YES NO
Stress test (e.g. exercise ECG) Proceed to discharge patient with urgent
using treadmill. cardiac follow-up (on upgraded medical
therapy) according to long-term
management after control of myocardial
ischemia.
Variables Used in the TIMI Risk Score
• Variable
1.7 per 10 y
2.0 per class
• Older age Killip
1.4 per 20 mm Hg ↑
class Systolic
2.4 BP
• ST-segment
4.3 deviation
2.per 1-mg/dL ↑
• Cardiac arrest during presentation
1.6
• Serum3.per
creatinine level
30-beat/min
↑
• Positive initial cardiac biomarkers
• Heart rate
Management
• It Includes increasing myocardial oxygen demand delivery by improving
perfusion and decreasing myocardial oxygendemand.
• Reversing myocardial ischemia and confirming the diagnosis of ACS is
essential priority.
• Oxygen should be administered to patients with dyspnea, hypoxemia or
evidence of heart failure orshock.
• If precipitating reversible causes such as fever, anemia, hypoxemia,
infection, hypertension, anxiety, hyperthyroidism, arrhythmias or any drug
ingestion (eg cocaine, ephedrine) can be identified, they should be treated
aggressively.
• Further management includes relief of pain and anti- ischemic therepy,
therepy for platelet aggregation/thrombosis, ongoing risk stratification
and consideration of invasive reperfusionprocedures.
1. AntiIschemia
Therapy
2. Antiplatelettherapy
• The current guidelines recommend a loading dose of 300 to 600mg
of clopidogrel in patients of UA/NSTEMI, followed by 75 mg daily.
The duration of clopidogrel may depend upon whether or not the
patient has received stent.
Recommendation
Low risk : Aspirin + Anticoagulant + either a glycoprotein IIb/IIIa inhibitor or a
thienopyridine
High Risk: Aspirin + Anticoagulant + a glycoprotein IIb/IIIa inhibitor +a
thienopyridine
InterventionalManagement
• In patients with High Risk, following treatment with anti-ischemic and
antithrombotic agents, coronary arteriography is carried out within ~ 48 h of
admission, followed by coronary revascularization (PCI or coronary artery
bypass grafting), depending on the coronaryanatomy.
• In low-risk patients, the outcomes from
an invasive
which strategy
consists are similar to and
of anti-ischemic those
obtained from aconservative
antithrombotic strategy, by
therapy followed
“watchful waiting,” and in which coronary
arteriography is carried out only if rest pain
or ST-segment changes recur or there is
evidence of ischemia on a stresstest.
UA/NSTEMI
treatmentAlgorithm
Complications
• Ventricular dysfunction
• Cardiogenic shock
• Right Ventricular Infarction
• Pericarditis
• Thromboembolism
• Left ventricular aneurysm
• Sinus bradycardia
• AVBlock
• Ventricular tachycardia and fibrillation